Novo Nordisk launches weekly insulin alternative in India
Novo Nordisk has introduced Awiqli, a once-weekly insulin injection for patients with diabetes in India. The medication aims to reduce the frequency of injections from daily doses to one per week.
Amalgamated from Times of India (opens in new tab), Indian Express (opens in new tab), Indian Express (opens in new tab), Times of India (opens in new tab)
Novo Nordisk has launched Awiqli in India, a medication that provides an alternative to standard daily insulin injections. This new treatment allows patients with diabetes to receive their insulin once a week, which reduces the annual number of required injections to 52.
According to reports from the Times of India and Indian Express, the introduction of this product is intended to expand available options for patients. The goal of the offering is to help more people with diabetes transition away from daily injection cycles to a less frequent schedule. While the medication represents a significant expansion in clinical choices, doctors noted that it may not be suitable for every patient depending on individual needs.
The Indian Express reported that Awiqli is priced at 261 rupees per week. Several news outlets described the medication as a world first in its category of once-weekly insulin delivery. The availability of this option marks a significant change in the local pharmaceutical landscape for managing chronic metabolic conditions.
Why this matters
The introduction of weekly insulin could significantly improve patient compliance and quality of life for those who struggle with daily needle regimens. It also represents a major shift in how chronic diseases are managed within the Indian healthcare market.
What's confirmed / what isn't
The product name (Awiqli), the manufacturer (Novo Nordisk), and the reduction of injections from daily to weekly are confirmed by multiple news outlets. The specific price point of 261 rupees per week is reported by Indian Express.
Background
Insulin is a hormone that regulates blood sugar levels in the body. While standard treatments typically require daily administration, various long-acting formulations have been developed to reduce injection frequency for some patients.